Sonnet BioTherapeutics Holdings ( (SONN) ) has issued an announcement.
On February 26, 2025, Sonnet BioTherapeutics announced the presentation of data at the 2025 AACR IO Conference, highlighting the potential of their drug SON-1010 for treating solid tumors. The presentation showcased the company’s FHAB platform, which improves drug targeting and retention in tumors, potentially enhancing therapeutic outcomes. The data included ongoing trials of SON-1010 as a monotherapy and in combination with other treatments, showing promising results in patients with advanced solid tumors. These developments could significantly impact Sonnet’s positioning in the oncology field by addressing unmet needs and improving patient outcomes.
More about Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company that develops targeted biologic drugs using its proprietary Fully Human Albumin-Binding (FHAB) platform. This technology is designed to enhance the delivery and efficacy of immune-modulating biologic drugs by targeting tumor and lymphatic tissues. The company’s lead program, SON-1010, is in development for treating advanced solid tumors, sarcoma, and platinum-resistant ovarian cancer.
YTD Price Performance: -6.25%
Average Trading Volume: 1,075,752
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.6M
For detailed information about SONN stock, go to TipRanks’ Stock Analysis page.